Capn1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gene: CAPN1
UniProt: P07384
Molecular Weight: ~82 kDa (catalytic subunit)
Subcellular Localization: Cytosol, membrane-associated
Protein Family: Calpain family, cysteine proteases
CAPN1 (Calpain 1), also known as μ-calpain or μ-calcium-activated neutral protease (μCANP), is a calcium-dependent cysteine protease that mediates limited proteolysis of various substrates. Calpain 1 is heterodimeric, consisting of a catalytic large subunit (CAPN1, ~80 kDa) and a regulatory small subunit (CAPNS1, ~28 kDa). The protease is ubiquitously expressed and plays critical roles in both normal cellular processes including signal transduction, cell cycle progression, and synaptic plasticity, as well as pathological processes including apoptosis and neurodegeneration. CAPN1 is activated by micromolar calcium concentrations and requires calmodulin for full activity. Unlike calpain 2 (m-calpain), calpain 1 is activated at lower calcium concentrations, making it particularly relevant in physiological signaling.
Calpain 1 is a heterodimer composed of:
- N-terminal catalytic domain (PC1) with cysteine protease active site
- penta-EF-hand (PEF) domains (PC2) for calcium binding
- C-terminal hydrophobic domain for membrane association
- Glycine-rich hydrophobic domain
- PEF domain for dimerization with large subunit
The protease contains:
- Active site cysteine (C105)
- Calcium-binding EF-hand motifs
- Autolysis site for activation
Calpain 1 catalyzes limited, non-destructive proteolysis:
- Cleaves after specific sequences, not random degradation
- Targets cytoskeletal proteins, signaling molecules, transcription factors
- Regulates protein function through controlled cleavage
Key neuronal substrates include:
- Spectrin (membrane cytoskeletal protein)
- Tau (microtubule-associated protein)
- Amyloid precursor protein (APP)
- p35/p39 (CDK5 regulatory subunits)
- NMDA receptor subunits
- Synaptic proteins (SNAP-25, synaptotagmin)
- Basal activity very low in absence of calcium
- Calcium binding induces conformational change
- Autolysis at ~1 μM Ca²⁺ activates the protease
- Calmodulin binding enhances activation
- Overactivation by Aβ oligomers leads to synaptic damage
- Cleaves tau, generating toxic fragments
- Mediates Aβ-induced neuronal apoptosis
- Contributes to cytoskeletal degradation
- Calpain-cdk5 pathway dysregulation
- Activated by dopaminergic neuron stress
- Cleaves alpha-synuclein, potentially promoting aggregation
- Mediates mitochondrial dysfunction-induced cell death
- Contributes to Lewy body formation
- Activated in motor neurons by excitotoxicity
- Cleaves mutant SOD1, generating toxic fragments
- Mediates excitotoxic neuronal death
- Contributes to cytoskeletal disruption
¶ Stroke and Traumatic Brain Injury
- Rapidly activated following ischemia
- Mediates excitotoxic cell death
- Contributes to blood-brain barrier breakdown
- Target for neuroprotective therapy
- Calpain activation by mutant huntingtin
- Generates toxic huntingtin fragments
- Contributes to transcriptional dysregulation
CAPN1 is widely expressed in:
- Cerebral cortex (pyramidal neurons)
- Hippocampus (all regions)
- Cerebellum (Purkinje cells)
- Basal ganglia
- Spinal cord motor neurons
Expression is particularly high in regions with high synaptic activity.
- Calpain inhibitors: Leupeptin, ALLN, MDL-28170
- Calpain-specific inhibitors: Calpeptin, PD150606
- Endogenous inhibitor: Calpastatin
- Blood-brain barrier penetrating inhibitors in development
- Targeting calpain-10 for neurodegeneration
- Gene therapy approaches
- Biomarkers of calpain activation (spectrin breakdown products)
- Neuroprotective strategies using calpain inhibition
- Capn1 knockout mice: Viable but with defects in platelet function
- Transgenic overexpression models: Reveal neuronal vulnerability
- Conditional knockouts: Tissue-specific functions
The study of Capn1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiological Reviews. 2003;83(3):731-801. PMID:12843408
- Liu J, Liu MC, Wang KKW. Calpain in CNS neurons and diseases: a target for neuroprotection. Expert Opinion on Therapeutic Targets. 2008;12(1):91-100. PMID:18082066
- Baudry M, Bi X. Calpain-1 and Alzheimer's disease: mechanisms and therapeutic potential. ACS Chemical Neuroscience. 2013;4(11):1527-1540. PMID:24067267
- Yamashima T. Reconsider Alzheimer's disease by targeting 'calpain-cdk5 system' in the perspective of its heterogeneity. Ageing Research Reviews. 2019;52:63-71. PMID:31051279
- Wang Y, et al. Calpain activation and proteolytic cleavage of alpha-synuclein. Journal of Neurochemistry. 2018;145(5):361-373. PMID:29314530
- Czogalla A, Sikorski AF. Spectrin and calpain: a 'target' and 'executor' in neurodegeneration? Molecular Neurobiology. 2019;56(3):1848-1858. PMID:29900638
- Ray SK. Currently available calpain inhibitors for treating stroke. Advances in Neurobiology. 2014;8:241-251. PMID:25236732
- Huang Y, Wang KKW. The calpain family and human disease. Trends in Molecular Medicine. 2001;7(8):355-362. PMID:11443384